Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)

NCT03294577 is registered in ClinicalTrials.gov with BeyondSpring Pharmaceuticals Inc. as lead sponsor.

NCT NCT03294577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03294577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
October 23, 2019
Completion date
September 25, 2025
Enrollment
221 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia